We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00561301
Recruitment Status : Unknown
Verified November 2007 by Cooperative Study Group A for Hematology.
Recruitment status was:  Recruiting
First Posted : November 20, 2007
Last Update Posted : November 20, 2007
Sponsor:
Information provided by:

November 18, 2007
November 20, 2007
November 20, 2007
November 2006
Not Provided
objective response rate [ Time Frame: 10/2009 ]
Same as current
No Changes Posted
toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT [ Time Frame: 10/2009 ]
Same as current
Not Provided
Not Provided
 
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)
- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lymphoma
Drug: GemDOx
gemcitabine oxliplatin
No Intervention: 1
Intervention: Drug: GemDOx
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
43
October 2009
Not Provided

Inclusion Criteria:

  • Patients who have refractory to first-line CHOP-like regimen
  • Patients who have first relapse after
  • first-line CHOP-like regimen
  • upfront autologous or allogeneic hematopoietic stem cell transplantation
  • Age 15 years or more
  • ECOG performance status ≤ 2
  • Adequate bone marrow function
  • Adequate kidney,liver,cardiac

Exclusion Criteria:

  • Patients who have received GEM or OX
Sexes Eligible for Study: All
15 Years to 65 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT00561301
C-012A
No
Not Provided
Not Provided
Not Provided
Cooperative Study Group A for Hematology
Not Provided
Principal Investigator: Hawk Kim, professor Ulsan Universtity Hospital, ROK
Cooperative Study Group A for Hematology
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP